X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Ferinject (ferric carboxymaltose) is an Fe modulator, small molecule drug candidate. It is approved for the treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Ferinject (ferric carboxymaltose) is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Injectafer (ferric carboxymaltose injection) is indicated for the improvement of exercise capacity for iron deficient adult patients with symptomatic heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Injectafer
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2023
Details:
Injectafer (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with iron deficiency in adult patients with heart failure categorized.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Injectafer
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: American Regent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Orofer (ferric carboxymaltose) which is capable of releasing iron, helping in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Orofer
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Ferinject 50mg/ml Solution for Injection is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL
Deal Size: $11,700.0 million Upfront Cash: $11,700.0 million
Deal Type: Acquisition August 02, 2022
Details:
CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL
Deal Size: $11,700.0 million Upfront Cash: $11,700.0 million
Deal Type: Acquisition December 14, 2021
Details:
The U.S FDA has approved a single 1000 mg dose option of Injectafer®, ferric carboxymaltose injection, an iron replacement product, for iron deficiency anemia patients who have intolerance to oral iron, have low response to oral iron, or have non-dialysis dependent CKD.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Injectafer
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: M.D. Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
The study demonstrated there were significantly fewer hospital readmissions due to HF among patients treated with Ferinject® compared to placebo.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ferinject
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
A pre-specified sensitivity analysis considering the impact of the COVID-19 pandemic, revealed a statistically significant difference in favor of Ferinject® on cardiovascular mortality and hospitalization for heart failure.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
